Ovarian cancer (OC) is the 7th most common cancer in women globally
Highest mortality than any other cancer of the reproductive system
Facts
UKCTOCS (largest ovarian cancer screening trial) showed no decrease in mortality with current screening tools
Lack imaging technology to reliably visualize and differentiate benign vs malignant growth
US Preventive Task Force (USPTF) recommends against routine OC screening in the general population
Asymptomatic during early stages so already advanced during time of discovery.
Only 30.8% 5 year survival rate in Stage 4 advanced stage Ovarian Cancer according to the National Cancer Institute’s SEER Program (National Cancer Institute’s Surveillance, Epidemiology and End Results)
Opportunity
95% successful outcome with early stage detection; No clear market leader
OC is complex and a multi-modal, integrated approach is widely accepted as optimal
DACI is a platform technology, serving as accessory, predictive “value add” to existing tools
Accelerated Regulatory pathway as breakthrough solution for Orphan disease
